Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GlaxoSmithKline PLC (NYSE:GSK)

42.73
Delayed Data
As of Mar 29
 +0.32 / +0.75%
Today’s Change
37.20
Today|||52-Week Range
45.58
+10.96%
Year-to-Date
VBI Vaccines Emerges as Strong Biotech Stock
Mar 29 / TheStreet.com - Paid Partner Content
Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod
Mar 21 / Zacks.com - Paid Partner Content
GlaxoSmithKline Continues to Strengthen
Mar 29 / TheStreet.com - Paid Partner Content
6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
Mar 21 / Zacks.com - Paid Partner Content
J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe
Mar 27 / Zacks.com - Paid Partner Content
Lilly's Breast Cancer Combo Drug Phase III Results Positive
Mar 21 / Zacks.com - Paid Partner Content
Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma
Mar 27 / Zacks.com - Paid Partner Content
Novartis (NVS) Announces Positive Data on Heart Failure Drug
Mar 20 / Zacks.com - Paid Partner Content
Why Google Has to Definitively Address Its Offensive Content Problem
Mar 23 / TheStreet.com - Paid Partner Content
AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal
Mar 20 / Zacks.com - Paid Partner Content
Pernix: An Investor's Rationale to Staying Long
Mar 23 / GuruFocus News - Paid Partner Content
Why Biotech Stock Gilead (GILD) Could Be a Value Trap
Mar 20 / Zacks.com - Paid Partner Content
Novartis' Acute Heart Failure Drug Fails in Late-Stage Study
Mar 22 / Zacks.com - Paid Partner Content
Glaxo Files for Label Expansion of Influenza Vaccine in US
Mar 16 / Zacks.com - Paid Partner Content